Fedenia Advisers LLC Grows Position in Boston Scientific Corporation (NYSE:BSX)

Fedenia Advisers LLC boosted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 551.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 6,059 shares of the medical equipment provider's stock after acquiring an additional 5,129 shares during the period. Fedenia Advisers LLC's holdings in Boston Scientific were worth $611,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Brighton Jones LLC lifted its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG raised its stake in shares of Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the period. Highview Capital Management LLC DE lifted its holdings in Boston Scientific by 6.2% during the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares in the last quarter. SVB Wealth LLC purchased a new stake in Boston Scientific during the 4th quarter worth about $999,000. Finally, SRS Capital Advisors Inc. boosted its stake in Boston Scientific by 168.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,801 shares of the medical equipment provider's stock worth $161,000 after purchasing an additional 1,130 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of Boston Scientific stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $18,347,824.96. This trade represents a 24.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 461,970 shares of company stock worth $47,755,193 over the last 90 days. 0.50% of the stock is owned by insiders.

Boston Scientific Trading Up 0.6%

Shares of BSX stock traded up $0.67 on Friday, hitting $104.30. 2,931,148 shares of the company's stock traded hands, compared to its average volume of 6,666,246. The stock has a market capitalization of $154.30 billion, a price-to-earnings ratio of 76.13, a P/E/G ratio of 2.71 and a beta of 0.68. The company's fifty day simple moving average is $103.42 and its 200 day simple moving average is $100.14. Boston Scientific Corporation has a one year low of $71.88 and a one year high of $107.53. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The company's revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period last year, the firm earned $0.56 earnings per share. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BSX shares. Barclays increased their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Citigroup reaffirmed a "buy" rating and set a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Royal Bank Of Canada raised their price target on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Morgan Stanley boosted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Finally, Leerink Partners started coverage on shares of Boston Scientific in a report on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target on the stock. Twenty-two equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $116.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.